Efficacy of Tamsulosin Oral-controlled Absorption System (OCAS) in the Treatment of Distal Ureteral Stones
NCT ID: NCT01167062
Last Updated: 2010-07-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
120 participants
INTERVENTIONAL
2010-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Use of Tamsulosin in Treatment of (10-15 mm) Lower Ureteric Stones in Adults With Non-emergent Symptoms
NCT03274700
The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients
NCT00448123
Tamsulosin as Adjuvant Treatment Prior to Endoscopic Ureterolithotomy
NCT03614052
The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients
NCT00600405
Effect of Perioperative Selective alpha1-blockers in Non-stented Ureteroscopic Laser Lithotripsy for Ureteric Stones: A Randomized Controlled Trial
NCT04557202
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* All patients will receive 75 mg sodium diclofenac via intramuscular on demand
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo
One tablet OD for a maximum of 28 days
Tamsulosin Hydrochloride OCAS 0.4 mg
Tamsulosin Hydrochloride OCAS 0.4 mg
One tablet OD for a maximum of 28 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tamsulosin Hydrochloride OCAS 0.4 mg
One tablet OD for a maximum of 28 days
Placebo
One tablet OD for a maximum of 28 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who have distal ureteral stones with a size of 4-10 mm
* Written informed consent has been obtained.
Exclusion Criteria
* Patients with urinary tract infection
* Patient with diabetes and peptic ulcer
* Patient with renal dysfunction (elevated of serum creatinine level)
* Patients with severe hydronephrosis
* Patients with history of passing stones
* Pregnancy
* Patients who desire to withdraw from the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chiang Mai University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chiang Mai University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Maharat Nakhon Chiangmai Hospital
Muang, Chiangmai, Thailand
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TAM040-0109
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.